DBA variants in patients with cancer/MDS refer mainly to RPS19, RPL35A, RPL11, RPL5, RPS17, and GATA1 genes (18%, 13%, 10%, 5%, 3%, and 3%, respectively; 49% unknown) [47]. This evidence concerns the gene RPS19 and myelodysplastic syndrome.